Skip to content
Open access

Proximal Proteomics Reveals Potential Regulators of Programmed Death-Ligand 1 in Human Cancer

Aug 2026 · ACS Omega · Vol 11, pp. 50389 - 50405 · 0 citations · 40 references
Medicine

TL;DR

The found that C-terminal-proximal proteins were enriched in protein degradation, ER-associated quality control, and immune-related pathways, whereas N-terminal-proximal proteins were mainly associated with protein localization and intracellular transport.

Abstract

Programmed death-ligand 1 (PD-L1) is a key mediator of tumor immune evasion, but the protein networks governing its post-translational regulation remain incompletely understood. Here, we used PhastID-based proximity labeling to map the PD-L1 proximal proteome and integrated these data with pan-cancer proteomics and immunohistochemical analysis of clinical tumor samples. We found that C-terminal-proximal proteins were enriched in protein degradation, ER-associated quality control, and immune-related pathways, whereas N-terminal-proximal proteins were mainly associated with protein localization and intracellular transport. Integrated analysis identified CAND1, TXN, and FBXO2 as candidate PD-L1 regulators. Knockdown of CAND1, TXN, or FBXO2 reduced PD-L1 protein expression in cancer cells. Mechanistically, CAND1 interacted with PD-L1 and was detected in a complex containing PD-L1 and FBXO22. CAND1 depletion promoted K48-linked ubiquitination and degradation of PD-L1, while deletion of the PD-L1 intracellular domain or mutation of K271 and K281 attenuated PD-L1 ubiquitination. Functionally, CAND1 knockdown enhanced T cell-mediated tumor cell killing, and elevated CAND1 expression was associated with an immunosuppressive tumor microenvironment. Together, our findings define the PD-L1 proximal proteomic landscape and identify CAND1-mediated regulation of PD-L1 stability as a potential mechanism of tumor immune escape.

Read PDF

Similar papers

Open access 2026

AI-assisted design and virtual profiling of targeted degraders for pancreatic cancer therapy via PROTAC technology.

Pancreatic cancer remains one of the most lethal malignancies because of late diagnosis, aggressive progression, therapy resistance, and limited effective treatment options. Bromodomain-containing protein 4 (BRD4) is an important epigenetic regulator implicated in pancreatic cancer progression through its role in trans...

Bing-Yan Du, Kun-Jie Wang, Zhu Wu et al. · 0 citations
Review Open access Aug 2026

Deubiquitinating enzymes in kidney diseases: Molecular mechanisms, pathological roles and therapeutic opportunities (Review)

The ubiquitin-proteasome system maintains cellular protein turnover and quality control through the coordinated action of ubiquitin ligases and deubiquitinating enzymes (DUBs). While the functions of E3 ubiquitin ligases have been extensively investigated in renal disease, the ~100 human DUBs distributed across seven s...

Qianqian Li, Yufang Ni, Zhao-Yang Li et al. · 1 citation
Open access Sep 2026

Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer

This study identifies a novel ‘PD-L1–ER stress–pyruvate–macrophage senescence’ axis as a key mechanism underlying primary resistance to ICB and proposes that targeting the PDK4/GLS-dependent pyruvate surge offers a promising therapeutic strategy to sensitize tumors to anti-PD-1 immunotherapy.

Wen-Xin Lian, Hui Yang, Yu-Qi Zhang et al. · 0 citations
Review Oct 2026

RIPK1 kinase and scaffold activities in tumor cell fate and therapy.

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...

Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al. · 0 citations
Open access Sep 2026

Regulation of PD-L1 expression and secretion by branched-chain amino acids in melanoma and prostate cancer cells

Cancer immunotherapy, particularly immune checkpoint blockade targeting programmed death ligand 1 (PD-L1), has revolutionized cancer treatment. Branched-chain amino acids (BCAAs) are essential amino acids whose metabolism can be an indicator of certain cancers. However, the relationship between branched-chain amino aci...

Si-Yi Yang · 0 citations
Review Open access Aug 2026

Mechanistic Links Between Natural Bioactive Molecules and Tumor Immune Microenvironment States in PD-1/PD-L1 Resistance

Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade can produce durable responses, but primary and acquired resistance are common. Treatment outcome is influenced by antigen presentation, T-cell localization, suppressive myeloid populations, metabolic stress, and the gut microbiome, all of w...

Hui-Ya Cheng, Mei-Lun Chen, Min Xiao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.